Rocket Pharmaceuticals, Inc.

NASDAQ:RCKT

Biotechnology

Healthcare
$2.11 +1.84%

+$0.06 today

Market cap
$235.60M
Beta
0.47
P/E (TTM)
-1.7
EPS (TTM)
-$1.87
52W Low $2.40High $5.45

Volume 2.49M

Average 3.15M

RCKT Effect of Forex Changes

Change in reported cash caused by exchange-rate movements on foreign-currency balances.

Rocket Pharmaceuticals, Inc.NASDAQ: RCKT

Effect of Forex Changes · Q1 FY2026 · quarter ended Mar 2026

Effect of forex changes outflow grows to $0

Q1 FY2026 effect of forex changes was $0, compared with $0 a year earlier. Trailing-twelve-month effect of forex changes was $0.

Context

  • Effect of forex changes increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly effect of forex changes holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
LTMMar 2026
$0— YoY
Effect of Forex Changes past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Effect of Forex Changes history

USD · from the cash flow

Latest · FY2025
0 USD
Year-over-year change
—

Effect of Forex Changes vs competitors

How RCKT compares with its peers on the latest reported figures

  • RCKT's LTM Mar 2026 effect of forex changes of $0 is the 7th largest of the 10 companies compared; the peer median is $0.
RCKT Competitors Peer median
Effect of Forex Changes for RCKT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
DBVTDBV Technologies S.A.LTM Mar 2026$3.08M +481.2%——
AUTLAutolus Therapeutics plcLTM Mar 2026$732K -83.7%—0.8%
LBRXLB Pharmaceuticals Inc Common StockLTM Mar 2026$264K ———
AURAAura Biosciences, Inc.LTM Mar 2026$192K +814.3%——
QSIQuantum-Si incorporatedLTM Mar 2026$66K +371.4%—3.6%
ANNXAnnexon, Inc.LTM Mar 2026$3K +200.0%+26.0%—
RCKTRocket Pharmaceuticals, Inc.LTM Mar 2026$0 ———
SLDBSolid Biosciences Inc.LTM Mar 2026$0 +100.0%——
DSGNDesign Therapeutics, Inc.LTM Mar 2026$0 ———
GALTGalectin Therapeutics Inc.LTM Mar 2026$0 ———
Peer median (excluding RCKT) $0+285.7%+26.0%2.2%

Competitors are the stored peer set for RCKT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(169.07M)(221.86M)(245.6M)(258.75M)(223.12M)
Depreciation & Amortization5.37M6.27M7.1M9.38M11.03M
Deferred Income Tax3.15M0000
Stock-Based Compensation29.24M31.01M39.41M43.92M37.06M
Change in Working Capital(3.39M)6.08M13.46M1.92M(8.3M)
Accounts Receivables00000
Inventory00000
Accounts Payables(4.83M)9.67M000
Other Working Capital1.44M(3.6M)13.46M1.92M(8.3M)
Other Non-Cash Items13.53M370K(9.28M)(6.19M)(6.68M)
Operating Cash Flow(121.16M)(178.14M)(194.92M)(209.72M)(190.01M)
Capital Expenditures(7.72M)(8.62M)(16.47M)(5.86M)(440K)
Acquisitions (Net)95K42.73M000
Purchases of Investments(245.88M)(376.33M)(390.92M)(245.89M)(276.55M)
Sales of Investments272.44M272.89M309.33M383.45M380.76M
Other Investing Activities(95K)0000
Investing Cash Flow18.85M(69.33M)(98.07M)131.71M103.77M
Debt Repayment201K172K139K00
Common Stock Issued37.68M155.34M208.39M185.74M0
Common Stock Repurchased0(47K)00(67K)
Dividends Paid00000
Other Financing Activities(201K)(172K)(132K)0215K
Financing Cash Flow37.68M155.29M208.4M185.74M148K
Effect of Forex Changes00000
Net Change in Cash(64.63M)(92.18M)(84.58M)107.72M(86.1M)
Free Cash Flow(128.88M)(186.76M)(211.39M)(215.59M)(190.45M)

Rocket Pharmaceuticals, Inc.

NASDAQ:RCKT

Intrinsic Alpha fair value

Locked

Current Price

$2.11

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.